Tonix Pharmaceuticals Holding Corp. [TNXP] stock is down -3.49 while the S&P 500 has fallen -0.13% on Tuesday, 10/13/20. While at the time of this article, TNXP ATR is sitting at 0.06, with the beta value at 1.38. This stock’s volatility for the past week remained at 4.75%, while it was 7.52% for the past 30-day period. TNXP has fallen -$0.03 from the previous closing price of $0.77 on volume of 2.06 million shares.

On 7, October 2020, Tonix Pharmaceuticals to Participate in BIO Investor Forum Digital. According to news published on Yahoo Finance, Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will deliver a Company presentation and host one-on-one meetings during the 2020 BIO Investor Forum Digital, being held virtually October 13-15, 2020. The Company’s presentation will be available on demand to registered participants through the conference website.

Analyst Birdseye View:

The most recent analyst activity for Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] stock was on August 18, 2017, when it was Upgrade with a Buy rating from ROTH Capital, which also raised its 12-month price target on the stock to $6. Before that, on April 18, 2019, ROTH Capital Recapitulated a Buy rating and elevated its amount target to $4. On September 07, 2016, ROTH Capital Downgrade a Neutral rating. On February 17, 2016, Oppenheimer Reiterated an Outperform rating and decreased its price target from $18 to $10. On November 04, 2015, Cantor Fitzgerald Initiated a Buy rating. On June 12, 2015, Oppenheimer Initiated an Outperform rating and boosted its amount on this stock to $18. On February 17, 2015, ROTH Capital Reiterated a Buy rating and boosted its target amount on this stock from $10 to $12. ROTH Capital elevated its amount target by recapitulating a higher weight for this stock.

In the past 52 weeks of trading, this stock has oscillated between a low of $0.39 and a peak of $5.00. Right now, according to Wall Street analyst the average 12-month amount target is $3.00. At the most recent market close, shares of Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] were valued at $0.74.

FUNDAMENTAL ANALYSIS

If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 3.66 and the whole liability to whole assets at 2.46. It shows enduring liability to the whole principal at 0.06 and enduring liability to assets at 0.00 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 0.7478 points at 1st support level, the second support level is making up to 0.7289. But as of 1st resistance point, this stock is sitting at 0.7778 and at 0.7889 for 2nd resistance point.

Tonix Pharmaceuticals Holding Corp. [TNXP] reported its earnings at -$0.23 per share in the fiscal quarter closing of 6/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.22/share signifying the difference of -0.01 and -4.50% surprise value. Comparing the previous quarter ending of 3/30/2020, the stated earnings were -$0.37 calling estimates for -$0.31/share with the difference of -0.06 depicting the surprise of -19.40%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for Tonix Pharmaceuticals Holding Corp. [NASDAQ:TNXP] is 12.30. Likewise, the Quick ratio is also the same, showing Cash ratio at 2.19. Now if looking for a valuation of this stock’s amount to book ratio is 1.06.

Insider Stories

The most recent insider trade was by Treco James, Director, and it was the purchase of 5500.0 shares on Aug 31. Bell Margaret Smith, the Director, completed a purchase of 5391.0 shares on Aug 20. On Aug 17, SULLIVAN GREGORY M, Chief Medical Officer, completed a purchase of 20000.0 shares.